Exact Sciences Announces Mayo Clinic as First Healthcare System to Offer Cologuard®

Stool-based DNA (sDNA) screening test for colorectal cancer to be available by prescription to patients

MADISON, Wis. & ROCHESTER, Minn.--(BUSINESS WIRE)-- Exact Sciences Corp. (NASDAQ:EXAS) today announced that Mayo Clinic will be the first health system to offer Cologuard®, the first and only Food and Drug Administration (FDA) approved, noninvasive stool DNA screening test for colorectal cancer. Cologuard will be available to patients through their primary care physicians at Mayo Clinic.

Read More

Topics: Exact Sciences News

FDA Approves Exact Sciences’ Cologuard®; First and Only Stool DNA Noninvasive Colorectal Cancer Screening Test

Exact Sciences Corp. (NASDAQ: EXAS) announced today that the U.S. Food and Drug Administration (FDA) has approved Cologuard, the company’s noninvasive, stool DNA colorectal cancer screening test. Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers and has been proven to find 92 percent of cancers and 69 percent of the most advanced precancerous polyps in average risk patients. Cologuard, which is available through healthcare providers, offers people 50 and older at average risk for colorectal cancer an easy–to–use screening test they can do in the privacy of their own home.

Read More

Topics: Exact Sciences News